FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379280908> ?p ?o ?g. }

• W4379280908 endingPage "8012" @default.
• W4379280908 startingPage "8012" @default.
• W4379280908 abstract "8012 Background: Cilta-cel was FDA approved in 2022 for the treatment of RRMM. We evaluated the outcomes of patients treated with intended SOC cilta-cel. Methods: 12 US academic medical centers contributed data to this retrospective study. As of 12/31/2022, 177 patients were leukapheresed and 139 received cilta-cel. Results: The table describes the study population compared to the CARTITUDE-1 trial. More patients in our study had extramedullary disease (EMD, 35%) and high-risk cytogenetics (41%). 55% of the patients would not have met eligibility criteria for CARTITUDE-1. Common reasons for ineligibility were cytopenias (19%), prior BCMA therapy (14%), organ dysfunction (12%), oligosecretory disease (13%), and plasma cell leukemia (8%). 83% of the patients received bridging chemotherapy (overall response rate, ORR: 28%). Lymphodepletion included fludarabine (Flu) + cyclophosphamide (Cy): 81%, bendamustine: 11%, Cy: 4%, and cladribine + Cy: 4%. Median CAR-T cells infused were 0.6 million/kg (range: 0.1-0.9), and 19% of patients were treated on an expanded access protocol (EAP). Median follow-up was 2.3 months (range: 0-8). Cytokine release syndrome (CRS) was seen in 81% (≥ grade 3: 7%) and immune effector cell-associated neurotoxicity syndrome (ICANS) in 22% (≥ grade 3: 8%) of patients. Tocilizumab, steroids, and anakinra were used in 61%, 44%, and 10% of patients, respectively. Delayed neurotoxicity (NT) was seen in 9% (cranial nerve palsy: 8, Parkinsonism: 2, others: 3). Grade ≥ 3 cytopenias at day ≥ 30 were seen in 75% of patients. Infections were seen in 32% of patients. Day 30 (N=115) and best response rates (N=118) were: ≥ partial response (PR), 75/80%; ≥ very good PR, 44/62%; and ≥ complete response (CR), 26/40%, respectively. In the non-EAP FluCy population (N=88), best ORR/≥CR were 89/49%. 17 patients died by data cut-off, 4 due to disease progression and 13 (9%) due to non-relapse mortality (NRM) (grade 5 CRS: 3, infection: 6, CRS/infection: 1, grade 5 ICANS: 1, delayed NT: 2). Conclusions: Patients treated with intended SOC cilta-cel had a favorable ORR (80%) despite a larger proportion of patients having high-risk features relative to trial patients and limited follow-up. Response rates were higher in patients receiving conforming products with FluCy conditioning (89%). Delayed NT and NRM were seen in 9% of patients. Results will be updated with continued follow-up. D.K.H., K.K.P, M.J., Y.L. & S.S. contributed equally. [Table: see text]" @default.
• W4379280908 created "2023-06-05" @default.
• W4379280908 creator A5001877903 @default.
• W4379280908 creator A5005843572 @default.
• W4379280908 creator A5017390274 @default.
• W4379280908 creator A5024335882 @default.
• W4379280908 creator A5028564534 @default.
• W4379280908 creator A5032809521 @default.
• W4379280908 creator A5039680248 @default.
• W4379280908 creator A5042487436 @default.
• W4379280908 creator A5044719918 @default.
• W4379280908 creator A5047819225 @default.
• W4379280908 creator A5048939308 @default.
• W4379280908 creator A5053731124 @default.
• W4379280908 creator A5054360080 @default.
• W4379280908 creator A5060313982 @default.
• W4379280908 creator A5069049786 @default.
• W4379280908 creator A5071438752 @default.
• W4379280908 creator A5080882830 @default.
• W4379280908 creator A5081601392 @default.
• W4379280908 creator A5087799564 @default.
• W4379280908 creator A5090694142 @default.
• W4379280908 date "2023-06-01" @default.
• W4379280908 modified "2023-09-30" @default.
• W4379280908 title "Safety and efficacy of standard of care (SOC) ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM)." @default.
• W4379280908 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.8012" @default.
• W4379280908 hasPublicationYear "2023" @default.
• W4379280908 type Work @default.
• W4379280908 citedByCount "1" @default.
• W4379280908 countsByYear W43792809082023 @default.
• W4379280908 crossrefType "journal-article" @default.
• W4379280908 hasAuthorship W4379280908A5001877903 @default.
• W4379280908 hasAuthorship W4379280908A5005843572 @default.
• W4379280908 hasAuthorship W4379280908A5017390274 @default.
• W4379280908 hasAuthorship W4379280908A5024335882 @default.
• W4379280908 hasAuthorship W4379280908A5028564534 @default.
• W4379280908 hasAuthorship W4379280908A5032809521 @default.
• W4379280908 hasAuthorship W4379280908A5039680248 @default.
• W4379280908 hasAuthorship W4379280908A5042487436 @default.
• W4379280908 hasAuthorship W4379280908A5044719918 @default.
• W4379280908 hasAuthorship W4379280908A5047819225 @default.
• W4379280908 hasAuthorship W4379280908A5048939308 @default.
• W4379280908 hasAuthorship W4379280908A5053731124 @default.
• W4379280908 hasAuthorship W4379280908A5054360080 @default.
• W4379280908 hasAuthorship W4379280908A5060313982 @default.
• W4379280908 hasAuthorship W4379280908A5069049786 @default.
• W4379280908 hasAuthorship W4379280908A5071438752 @default.
• W4379280908 hasAuthorship W4379280908A5080882830 @default.
• W4379280908 hasAuthorship W4379280908A5081601392 @default.
• W4379280908 hasAuthorship W4379280908A5087799564 @default.
• W4379280908 hasAuthorship W4379280908A5090694142 @default.
• W4379280908 hasConcept C121608353 @default.
• W4379280908 hasConcept C126322002 @default.
• W4379280908 hasConcept C141071460 @default.
• W4379280908 hasConcept C2776694085 @default.
• W4379280908 hasConcept C2776755627 @default.
• W4379280908 hasConcept C2777701055 @default.
• W4379280908 hasConcept C2779263901 @default.
• W4379280908 hasConcept C2779338263 @default.
• W4379280908 hasConcept C2780653079 @default.
• W4379280908 hasConcept C2780850621 @default.
• W4379280908 hasConcept C2908647359 @default.
• W4379280908 hasConcept C3875195 @default.
• W4379280908 hasConcept C71924100 @default.
• W4379280908 hasConcept C90924648 @default.
• W4379280908 hasConcept C99454951 @default.
• W4379280908 hasConceptScore W4379280908C121608353 @default.
• W4379280908 hasConceptScore W4379280908C126322002 @default.
• W4379280908 hasConceptScore W4379280908C141071460 @default.
• W4379280908 hasConceptScore W4379280908C2776694085 @default.
• W4379280908 hasConceptScore W4379280908C2776755627 @default.
• W4379280908 hasConceptScore W4379280908C2777701055 @default.
• W4379280908 hasConceptScore W4379280908C2779263901 @default.
• W4379280908 hasConceptScore W4379280908C2779338263 @default.
• W4379280908 hasConceptScore W4379280908C2780653079 @default.
• W4379280908 hasConceptScore W4379280908C2780850621 @default.
• W4379280908 hasConceptScore W4379280908C2908647359 @default.
• W4379280908 hasConceptScore W4379280908C3875195 @default.
• W4379280908 hasConceptScore W4379280908C71924100 @default.
• W4379280908 hasConceptScore W4379280908C90924648 @default.
• W4379280908 hasConceptScore W4379280908C99454951 @default.
• W4379280908 hasIssue "16_suppl" @default.
• W4379280908 hasLocation W43792809081 @default.
• W4379280908 hasOpenAccess W4379280908 @default.
• W4379280908 hasPrimaryLocation W43792809081 @default.
• W4379280908 hasRelatedWork W1987332404 @default.
• W4379280908 hasRelatedWork W2044556191 @default.
• W4379280908 hasRelatedWork W2054306207 @default.
• W4379280908 hasRelatedWork W2078083587 @default.
• W4379280908 hasRelatedWork W2138623801 @default.
• W4379280908 hasRelatedWork W2165876757 @default.
• W4379280908 hasRelatedWork W2792230705 @default.
• W4379280908 hasRelatedWork W2801454081 @default.
• W4379280908 hasRelatedWork W2946618690 @default.
• W4379280908 hasRelatedWork W4239886120 @default.
• W4379280908 hasVolume "41" @default.
• W4379280908 isParatext "false" @default.
• W4379280908 isRetracted "false" @default.

• next